byiShook Opinion
Nov 11, 2024 - 13:35
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies. The post Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' appeared first on Investor's Business Daily.
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
The post Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' appeared first on Investor's Business Daily.